New MMIT research highlights payers’ continued hesitancy toward PDTs. Here’s what manufacturers need to know.
Jayne Hornung
Advertisement
Chief clinical officer, MMIT (Managed Markets Insight & Technology).
Articles by Jayne Hornung
Advertisement
Latest Updated Articles
When Will Payers Improve Coverage of Prescription Digital Therapeutics?Published: July 22nd 2022 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
Mark Cuban Pushes for Generic Drug Fee Waivers, as Cost Plus Drugs Eyes US Manufacturing Expansion
2
FDA Approves Breyanzi for Adults with Relapsed or Refractory Marginal Zone Lymphoma
3
FDA Appoints Tracy Beth Høeg as Acting Director of CDER
4
Pharmaceutical Executive Daily: FDA Names Tracy Beth Høeg as Acting Director of CDER
5
